

Regdanvimab reduced COVID-19 risk: real-time meta-analysis of 12 studies

@CovidAnalysis, September 2026, Version 11 (V1 2023), c19early.org/rgmeta.html

Abstract

Significantly lower risk is seen for mortality, hospitalization, progression, and recovery. 10 studies from 7 independent teams (all from the same country) show significant benefit.


Meta-analysis using the most serious outcome reported shows 55% [30-72%] lower risk. Results are similar for higher quality studies and worse for Randomized Controlled Trials.

Results are robust—in worst case exclusion sensitivity analysis 6 of 12 studies must be excluded before statistical significance is lost.

Efficacy is variant dependent. *In Vitro* research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5¹, XBB.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1². mAb use may create new variants that spread globally³⁻⁵, and may be associated with increased risk of autoimmune disease⁶, prolonged viral loads, clinical deterioration, and immune escape^{4,7-11}.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. All data and sources to reproduce this analysis are in the appendix.

Serious Outcome Risk



REGDANVIMAB FOR COVID-19 — HIGHLIGHTS

Regdanvimab reduced risk with very high confidence for mortality, hospitalization, progression, and in pooled analysis, and high confidence for recovery.

While effective when tested, regdanvimab may have reduced or no activity for recent variants.

39th treatment shown effective in March 2022, now with $p = 0.00049$ from 12 studies, recognized in 27 countries.

Real-time updates and corrections with a consistent protocol for 226 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

Introduction

Immediate treatment recommended

SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems,

which may lead to cytokine storm, pneumonia, ARDS, neurological injury¹³⁻²⁹ and cognitive deficits^{16,21}, cardiovascular complications³⁰⁻³⁶, DNA damage³⁷⁻⁴⁰, organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits⁴¹—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Minimizing replication as early as possible is recommended.

Many treatments are expected to modulate infection


SARS-CoV-2 infection and replication involves the complex interplay of 500+ host and viral proteins and other factors^{A,42-49}, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 12,000 compounds may reduce COVID-19 risk⁵⁰, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Monoclonal antibodies

Regdanvimab is a monoclonal antibody (mAb). mAbs are laboratory-engineered proteins designed

Evolution of COVID-19 clinical evidence

Meta-analysis results over time



c19early.org
September 2026

	Bamlanivimab/ etesevimab	Casirivimab/ imdevimab	Sotrovimab	Bebtelovimab	Tixagevimab/ cilgavimab
Alpha B.1.1.7					
Beta/ Gamma BA.1.351/ P.1					
Delta B.1.617.2					
Omicron BA.1/ BA.1.1					
Omicron BA.2					
Omicron BA.5					
Omicron BA.4.6					
Omicron BQ.1.1					

Table 1. Predicted efficacy by variant from Davis et al. (not updated for more recent variants). ■: likely effective ■: likely ineffective ■: unknown. Submit updates.

to mimic the immune system's ability to fight pathogens. In the context of COVID-19, mAbs typically target specific regions of the SARS-CoV-2 spike protein, inhibiting viral entry into human cells and neutralizing the virus. These antibodies are derived from the B cells of recovered patients or immunized animals and are produced in large quantities using recombinant DNA technology and cell culture methods.

Analysis

We analyze all significant controlled studies of regdanvimab for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random-effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, Randomized Controlled Trials (RCTs), and higher quality studies.

Treatment timing

Fig. 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to pre-

vent or minimize infection. Early treatment refers to treatment immediately or soon after symptoms appear, while late treatment refers to more delayed treatment.

Variant Dependence

Extensive mutations in SARS-CoV-2 have resulted in variants that evade neutralizing antibodies from monoclonal antibody treatments^{51,52}, resulting in efficacy that is highly variant dependent. Table 1 shows efficacy by variant for several monoclonal antibodies. This table covers earlier SARS-CoV-2 variants and has not been updated for more recent variants and more recent monoclonal antibodies.

Results

Table 2 summarizes the results for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Table 3 shows results by treatment stage. Fig. 3 shows a timeline of the results in regdanvimab studies. Fig. 4 plots

individual results by treatment stage. Fig. 5, 6, 7, 8, 9, 10, 11, and 12 show forest plots for random-effects meta-analysis of all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, and viral clearance.




Fig. 2. Treatment stages.

	Relative Risk	Studies	Patients
All studies	0.45 [0.28-0.70] ***	12	7,507
After exclusions	0.46 [0.27-0.79] **	11	7,277
RCTs	0.90 [0.13-6.11]	2	1,622
Mortality	0.37 [0.21-0.63] ***	7	3,945
Ventilation	0.52 [0.14-1.91]	4	2,124
ICU admission	0.41 [0.07-2.19]	2	1,693
Hospitalization	0.85 [0.79-0.93] ***	6	3,432
Recovery	0.59 [0.37-0.93] *	4	2,017
Viral	0.98 [0.62-1.56]	3	1,614

Table 2. Random-effects meta-analysis for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Results show the relative risk with treatment and the 95% confidence interval. * $p < 0.05$ ** $p < 0.01$ *** $p < 0.001$.

	Early treatment	Late treatment
All studies	0.46 [0.29-0.73] ***	0.14 [0.01-2.56]
After exclusions	0.48 [0.28-0.83] **	0.14 [0.01-2.56]
RCTs	0.90 [0.13-6.11]	
Mortality	0.38 [0.22-0.66] ***	0.14 [0.01-2.56]
Ventilation	0.52 [0.14-1.91]	
ICU admission	0.41 [0.07-2.19]	
Hospitalization	0.85 [0.79-0.93] ***	
Recovery	0.59 [0.37-0.93] *	
Viral	0.98 [0.62-1.56]	

Table 3. Random-effects meta-analysis results by treatment stage. Results show the relative risk with treatment and the 95% confidence interval. * $p < 0.05$ ** $p < 0.01$ *** $p < 0.001$.

Timeline of COVID-19 regdanvimab studies (pooled effects)




Fig. 3. Timeline of results in regdanvimab studies. The marked dates indicate the time when efficacy was known with a statistically significant improvement of $\geq 10\%$ from ≥ 3 studies for pooled outcomes and one or more specific outcome.

Efficacy in COVID-19 regdanvimab studies (pooled effects)




Fig. 4. Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random-effects meta-analysis.

12 regdanvimab COVID-19 studies


c19early.org
September 2026

Fig. 5. Random-effects meta-analysis for all studies. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

7 regdanvimab COVID-19 mortality results


c19early.org
September 2026

Fig. 6. Random-effects meta-analysis for mortality results.

4 regdanvimab COVID-19 mechanical ventilation results

c19early.org

September 2026




Fig. 7. Random-effects meta-analysis for ventilation.

2 regdanvimab COVID-19 ICU results

c19early.org

September 2026




Fig. 8. Random-effects meta-analysis for ICU admission.

6 regdanvimab COVID-19 hospitalization results

c19early.org

September 2026




Fig. 9. Random-effects meta-analysis for hospitalization.

4 regdanvimab COVID-19 progression results

c19early.org
September 2026




Fig. 10. Random-effects meta-analysis for progression.

4 regdanvimab COVID-19 recovery results

c19early.org
September 2026




Fig. 11. Random-effects meta-analysis for recovery.

3 regdanvimab COVID-19 viral clearance results

c19early.org
September 2026




Fig. 12. Random-effects meta-analysis for viral clearance.

Randomized Controlled Trials (RCTs)

Fig. 13 shows a comparison of results for RCTs and observational studies. Fig. 14 and 15 show forest plots for random-effects meta-analysis of all Randomized Controlled Trials and RCT mortality results. RCT results are included in Table 2 and Table 3.

Efficacy in COVID-19 regdanvimab studies (pooled effects)

c19early.org
September 2026




Fig. 13. Results for RCTs and observational studies.

RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases⁵⁴, and analysis of double-blind RCTs has identified extreme levels of bias⁵⁵. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or other organizations with conflicts of interest, for example governments that previously denied treatment with the study drug. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. *Bekelman et al.* and *Lundh et al.* show that industry-sponsored studies are more likely to be favorable. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 226 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates.

We performed a similar analysis across the 226 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03]⁶². Similar results are found for all low-cost treatments, RR 0.98 [0.90-1.06]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data.

COVID-19 RCT vs. observational results from 6,000+ studies




Fig. 16. For COVID-19, observational study results do not systematically differ from RCTs, RR 0.97 [0.91-1.03] across 226 treatments⁵⁹.

Lee et al. showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see^{64,65}.

RCTs may be less reliable

Concato et al. report a paradoxical finding—RCT results had higher variability, and only RCTs were found to sometimes report significant results the opposite of the overall result. The same trend is seen for the most popular (most politicized) COVID-19 treatments—considering all statistically significant results reported in studies, RCTs are slightly more likely to report a result in the opposite direction. In other words, for these COVID-19 treatments and for the topics covered by *Concato et al.*, assuming causality from a single study is more likely to result in an incorrect conclusion for RCTs.

Increased risk of inconsistent results for RCTs suggests higher prevalence of bias, which may arise due to many issues including design bias, conflicts of interest, treatment differences by physicians aware of allocation, attrition bias, ascertainment bias, randomization failures, errors, or fraud.

Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as $\geq 10\%$ decreased risk or $>0\%$ increased risk from ≥ 3 studies. Of these, 54% have been confirmed in RCTs, with a mean delay of 7.8 months (62% with 8.7 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

All studies must be carefully analyzed

Neither observational studies nor RCTs prove causation—any study can be flawed or fraudulent. We need much more, for example a combination of results from many independent teams, detailed understanding of each study, knowledge of conflicts/team reliability, dose-response relationships, delay-response relationships, logical results across outcomes, or details consistent with pre-clinical expectations.

All studies must be evaluated individually. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta-analyses.

2 regdanvimab COVID-19 Randomized Controlled Trials

c19early.org
September 2026




Fig. 14. Random-effects meta-analysis for all Randomized Controlled Trials. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

1 regdanvimab COVID-19 RCT mortality result

c19early.org
September 2026




Fig. 15. Random-effects meta-analysis for RCT mortality results.

Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which can be easily influenced by potential bias, may ignore or underemphasize serious issues not captured in the checklists, and may overemphasize issues unlikely to alter outcomes in specific cases (for example certain specifics of randomization with a very large effect size and well-matched baseline characteristics).

The studies excluded are as below. Fig. 17 shows a forest plot for random-effects meta-analysis of all studies after exclusions.

Lee (B), minimal details provided.

11 regdanvimab COVID-19 studies after exclusions

c19early.org
September 2026




Fig. 17. Random-effects meta-analysis for all studies after exclusions. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

Media Bias

Low-cost treatments were subject to bias and censorship during the pandemic. Scientific bias is seen in the design, analysis, presentation, and selective re-


porting of studies, which favored negative results. A similar bias is seen in the media coverage for low-cost treatments. However, the opposite is seen for high-profit treatments.

We analyze media coverage for the 226 treatments we cover using Altmetric⁶⁷, which reports the number of ~12,000 tracked news outlets that covered each study⁶⁸. Studies are considered to have received significant media coverage if they were covered by at least 0.5% of the tracked news outlets. Fig. 18, 19, and 20 show the bias toward positive results for high-profit treatments, in contrast to the opposite bias for low-cost treatments. This may result in widespread incorrect perceptions on the relative efficacy of high-profit and low-cost treatments. The impact is significant—increased cost limits the use of high-profit treatments and treatment equity, and high-profit treatments were also more difficult to access, especially for earlier treatment which improves efficacy and minimizes community transmission.

Media coverage was highly biased High-profit: preferred positive results Low-cost: preferred negative results

Media preferred to cover positive results for high-profit treatments.
And negative/inconclusive results for low-cost treatments.

Randomized trials only



Many studies show lower risk with low-cost treatments 98% of these were not covered by the media

Coverage of positive vs. negative/inconclusive results; whiskers are 95% confidence intervals.
Data from Altmetric. Log scale. See: c19early.org/msm.html

Fig. 18. Media was more likely to cover negative or inconclusive results for low-cost treatments, and positive results for high-profit treatments.

Media coverage for COVID-19 high-profit treatments

Media selectively covered positive studies for high-profit treatments

28 positive studies were covered:

tocilizumab (5), paxlovid (5), conv. plasma (4), casirivimab/... (3), molnupiravir (3), remdesivir (2), peg. lambda (2), sargramostim (2), sarilumab, tixagevimab/c...

11 negative studies were covered:

remdesivir (4), conv. plasma (2), molnupiravir, bebtelovimab, sotrovimab, bamlan./e..., paxlovid

97% of negative studies were not covered:



Data from Altmetric: studies receiving significant mainstream media coverage from 6,000+ studies for 226 treatments

Media censorship for COVID-19 low-cost treatments

Media selectively covered negative studies for low-cost treatments

c19early.org

September 2026

Only 18 positive studies were covered:

fluvoxamine (3), HCQ (7), antiandrogens (2), budesonide (2), vitamin D, melatonin, probiotics, ivermectin, cannabidiol, famotidine, curcumin, resveratrol, UDCA

98% of studies showing significantly lower risk were censored:

53 negative studies were covered:

HCQ (15), ivermectin (7), lopinavir/r... (5), vitamin D (5), azithromycin (4), zinc (2), vitamin C (2), metformin (2), fluvoxamine (2), indomethacin, colchicine, selenium, probiotics, vitamin A, ibuprofen, antiandrogens, vitamin B9, cannabidiol

Data from Altmetric: studies receiving significant mainstream media coverage from 6,000+ studies for 226 treatments

Fig. 20. In contrast to the results for high-profit treatments, mainstream media was biased against positive results for low-cost treatments.

A combination of factors may have led to the media's suppression of low-cost treatments:

- Politicization led to a media environment where coverage was often framed to support a political narrative rather than to provide objective scientific information. As Scott Alexander said: "if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele." There was strong social pressure to discredit low-cost treatments.
- Censorship of information conflicting with selected authorities. For example, individuals and organizations presenting conflicting science were often banned on Twitter and YouTube.
- FDA requires "no adequate, approved, and available alternatives" in order to grant an EUA for novel high-profit interventions, creating a strong incentive for authorities to ignore or downplay existing low-cost treatments.
- Regulatory capture biases authorities towards high-profit interventions.
- Authorities ignored most evidence for low-cost treatments, for example the NIH references only 2% of studies in delayed, rarely-updated, biased commentaries with no quantitative analysis.
- Media coverage of science is often not very accurate, e.g., misunderstanding confounding issues. For example the media widely considered the RECOVERY HCQ RCT to be conclusive on efficacy, but very late treatment of late stage patients (mostly on oxygen already) with an excessive toxic dose (shown dangerous in a dose comparison RCT) provides no information on the recommended early/prophylactic treatment. With difficulting in understanding basic confounders like treatment delay and dose, the media may favor deferring to authorities. Many studies for low-cost treatments require greater expertise to analyze. Relatively few journalists have a strong ability to analyze clinical trials and are outnumbered by the rest.
- Substantial funding from pharmaceutical advertising biases editorial decisions towards high-profit interventions.
- PR power - companies/teams with strong PR presence are favored in the media, which correlates with high-profit and high conflict of interest studies.
- The media was very negative in general, inflating risk, fear, and anxieties. A negative bias may improve ratings and revenue, increasing motivation to continue watching coverage. A combination of low-cost treatments greatly reducing risk conflicts with the negative narrative.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours^{69,70}. Baloxavir marboxil studies for influenza also show that treatment delay is critical — *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases ⁷¹
<24 hours	-33 hours symptoms ⁷²
24-48 hours	-13 hours symptoms ⁷²
Inpatients	-2.5 hours to improvement ⁷³

Table 4. Studies of baloxavir marboxil for influenza show that early treatment is more effective.

Fig. 21 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 226 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.




Fig. 21. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 226 treatments.

Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants⁷⁵, for example the Gamma variant shows significantly different characteristics⁷⁶⁻⁷⁹. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants^{80,81}.

Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic⁸⁴⁻¹⁰⁸, therefore efficacy may depend strongly on combined treatments.

Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta-analysis

The distribution of studies will alter the outcome of a meta-analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta-analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta-analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Pooled effects are no longer required to show efficacy as of March 2022

This section validates the use of pooled effects for COVID-19, which enables earlier detection of efficacy, however pooled effects are no longer required for regdanvimab as of March 2022. Efficacy is now known based on specific outcomes.

Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. "The studies reported different outcomes" is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.

Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Analysis of the the association between different outcomes across studies from all 226 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Fig. 22 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.0000000001$). Similarly, Fig. 23 shows that improved recovery is very strongly associated with lower mortality ($p < 0.0000000001$). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Fig. 24 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.00000000074$ to $p = 0.00000000015$.




Fig. 22. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.




Fig. 23. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.




Fig. 22. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as $\geq 10\%$ decreased risk or $> 0\%$ increased risk from ≥ 3 studies. 85% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.6 months. When restricting to RCTs only, 53% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.5 months. Fig. 25 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.




Fig. 25. The time when studies showed that treatments were effective, defined as statistically significant improvement of $\geq 10\%$ from ≥ 3 studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as differences in treatment delay are more likely to hide efficacy.

Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta-analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Discussion

Publication bias

Publishing is often biased towards positive results. Trials with patented drugs may have a financial conflict of interest that results in positive studies being more likely to be published, or bias towards more positive results. For example with molnupiravir, trials with negative results remain unpublished to date (CTRI/2021/05/033864 and CTRI/2021/08/0354242). For regdanvimab, there is currently not enough data to evaluate publication bias with high confidence.

Early treatment was common

Studies for regdanvimab were mostly early treatment studies, in contrast with typical low-cost treatments that were more likely to be tested with late treatment.

Funnel plot analysis

Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Fig. 27 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry ($p > 0.05$). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, $p < 0.0001$, with six variants of Egger's test all showing $p < 0.05$ ¹¹⁰⁻¹¹⁷. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.




Fig. 26. Early treatment was more common for high-profit drugs.




Fig. 27. Example funnel plot analysis for simulated perfect trials.

Limitations

Summary statistics from meta-analysis necessarily lose information. As with all meta-analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone⁸⁴⁻¹⁰⁸. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Notes

1 of the 12 studies compare against other treatments, which may reduce the effect seen. Currently all studies are peer-reviewed.

Reviews

Multiple reviews cover regdanvimab for COVID-19, presenting additional background on mechanisms and related results, including^{52,118}.

Other studies

Additional preclinical or review papers suggesting potential benefits of regdanvimab for COVID-19 include¹³⁰⁻¹³⁹. We have not reviewed these studies in detail.

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 500+ host and viral proteins and other factors⁴²⁻⁴⁹, providing many therapeutic targets. Over 12,000 compounds have been predicted to reduce COVID-19 risk⁵⁰, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Fig. 28 shows an overview of the results for regdanvimab in the context of multiple COVID-19 treatments, and Fig. 29 shows a plot of efficacy vs. cost for COVID-19 treatments.

Efficacy in COVID-19 studies (pooled effects)

c19early.org
September 2026




Fig. 28. Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random-effects meta-analysis. 0.5% of 12,000+ proposed treatments show efficacy¹⁴⁰.

Efficacy vs. cost for COVID-19 treatments

c19early.org
September 2026




Fig. 29. Efficacy vs. cost for COVID-19 treatments.

Conclusion

Studies to date show that regdanvimab is an effective treatment for COVID-19. Significantly lower risk is seen for mortality, hospitalization, progression, and recovery. 10 studies from 7 independent teams (all from the same country) show significant benefit. Meta-analysis using the most serious outcome report-

ed shows 55% [30-72%] lower risk. Results are similar for higher quality studies and worse for Randomized Controlled Trials.

Results are robust—in worst case exclusion sensitivity analysis 6 of 12 studies must be excluded before statistical significance is lost.

Efficacy is variant dependent. *In Vitro* research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5¹, XBB.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1². mAb use may create new variants that spread globally³⁻⁵, and may be associated with increased risk of autoimmune disease⁶, prolonged viral loads, clinical deterioration, and immune escape^{4, 7-11}.

Contact. Contact us on X at @CovidAnalysis.

Funding. We have received no funding or compensation in any form, and do not accept donations. This is entirely volunteer work.

Conflicts of interest. We have no conflicts of interest. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

Disclaimer. We do not provide medical advice. No treatment is 100% effective, and all may have side effects. Protocols combine multiple treatments. Consult a qualified physician for personalized risk/benefit analysis.

AI. We use AI models (Gemini, Grok, Claude, and ChatGPT) tasked with functioning as additional peer-reviewers to check for errors, suggest improvements, and review spelling and grammar. Any corrections are manually verified. Our preference for em dashes is independent of AI.

Updates. Our COVID-19 meta-analyses involve the extraction of over 227,000 datapoints from thousands of papers for 226 treatments. We thank the thousands of scientists, physicians, and other contributors that have provided updates, suggestions, feedback, and corrections. These are all welcome and can be submitted at <https://c19early.org/rgmeta.html>.


Dedication. This work is dedicated to top evidence-based physicians that worked tirelessly to analyze evidence and greatly reduce mortality and morbidity during the pandemic. In alphabetical order: Dr. Thomas J. Borody, Dr. Mary Talley Bowden, Dr. Flavio Cadegiani, Dr. Shankara Chetty, Dr. Ryan Cole, Dr. George Fareed, Dr. Sabine Hazan, Dr. Pierre Kory, Dr. Tess Lawrie, Dr. Robert Malone, Dr. Paul Marik, Dr. Peter McCullough, Dr. Didier Raoult, Dr. Harvey Risch, Dr. Jackie Stone, Dr. Brian Tyson, Dr. Joseph Varon, and Dr. Vladimir Zelenko.

Public domain. This is a public domain work distributed in accordance with the Creative Commons CC0 1.0 Universal license, which dedicates the work to the public domain by waiving all rights worldwide under copyright law. You can distribute, remix, adapt, and build upon this work in any medium or format, including for commercial purposes, without asking permission. Referenced material and third-party images retain any original copyrights or restrictions. See: <https://creativecommons.org/publicdomain/zero/1.0/>.

Study Notes

Chae

Regdanvimab Chae et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 124 patients in South Korea (March - May 2021)
Lower ventilation with regdanvimab (not stat. sig., $p=0.46$)


Chae et al., Tropical Medicine and Inf., Mar 2022

c19early.org

Retrospective 124 hospitalized severe COVID-19 patients receiving oxygen and remdesivir treatment in South Korea. A subgroup of 25 patients also received the monoclonal antibody regdanvimab prior to remdesivir. The regdanvimab subgroup had significantly more oxygen-free days (primary outcome), higher oxygen saturation, less advanced respiratory support, and shorter oxygen supplementation duration compared to the remdesivir alone group.

Choi

Regdanvimab Choi et al. LATE TREATMENT



Is late treatment with regdanvimab beneficial for COVID-19?

Retrospective 398 patients in South Korea

Lower need for oxygen therapy with regdanvimab ($p=0.004$)


Choi et al., Infection & Chemotherapy, Mar 2022

c19early.org

Retrospective 398 hospitalized mild-to-moderate COVID-19 patients in South Korea eligible for regdanvimab treatment. 65 patients received regdanvimab, with significantly lower supplemental oxygen requirements (6.2% vs 20.1% in controls). After adjusting for potential confounders, regdanvimab remained associated with lower risk of requiring supplemental oxygen (OR 0.20). There was no significant difference in mortality or hospitalization time in unadjusted results.

Fomina

Regdanvimab Fomina et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?

Prospective study of 77 patients in Russia (August 2022 - February 2023)

Study compares with tixagevimab/cilgavimab

Worse viral clearance with regdanvimab ($p=0.0084$)


Fomina et al., Frontiers in Immunology, Oct 2023

c19early.org

Prospective study of 77 COVID-19 outpatients showing improved efficacy with tixagevimab/cilgavimab compared to regdanvimab during Omicron variant dominance.

Hwang

Regdanvimab Hwang et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 378 patients in South Korea (May 2021 - January 2022)
Lower need for oxygen therapy with regdanvimab ($p=0.01$)


Hwang et al., Infectious Diseases and ..., Apr 2024

c19early.org

PSM retrospective 378 hospitalized COVID-19 patients in Korea showing lower progression with regdanvimab treatment.

Jang

Regdanvimab Jang et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 722 patients in South Korea (September 2020 - October 2021)
Shorter hospitalization ($p<0.0001$) and lower oxygen therapy ($p<0.0001$)


Jang et al., Int. J. Infectious Diseases, Jan 2023

c19early.org

Retrospective 722 hospitalized mild-to-moderate COVID-19 patients in Korea showing lower risk of disease progression with regdanvimab treatment.

Jang

Regdanvimab Jang et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 210 patients in South Korea (September 2020 - July 2021)
Lower need for oxygen therapy ($p<0.0001$) and higher discharge ($p=0.025$)


Jang et al., Current Therapeutic Resea..., May 2022

c19early.org

Retrospective 317 hospitalized mild-moderate COVID-19 patients in South Korea showing significantly lower rates of oxygen desaturation ($SpO_2 < 94\%$) at 28 days (primary outcome) with regdanvimab monoclonal antibody treatment (13%) compared to standard of care (40%). Regdanvimab also showed benefits in time to fever recovery, discharge rates, and supplemental oxygen use.

Kim

Regdanvimab Kim et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 2,214 patients in South Korea (Dec 2020 - Sep 2021)
Lower progression ($p=0.00018$) and lower oxygen therapy ($p<0.0001$)


Kim et al., Frontiers in Cellular and ..., May 2023

c19early.org

Retrospective 2,214 mild/moderate COVID-19 patients in South Korea, 1,095 treated with regdanvimab, showing lower oxygen requirements and lower progression to severe disease with treatment in the overall cohort, but not within the delta subset.

Kim

Regdanvimab Kim et al. EARLY TREATMENT RCT



Is early treatment with regdanvimab beneficial for COVID-19?
Double-blind RCT 1,315 patients in multiple countries (Jan - Apr 2021)
Lower need for oxygen therapy ($p<0.0001$) and lower hospitalization ($p<0.0001$)

Kim et al., Open Forum Infectious Dise..., Aug 2022

c19early.org

RCT 1,315 outpatients in South Korea, showing lower progression and improved recovery with regdanvimab.

Lee

Regdanvimab Lee et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 230 patients in South Korea (December 2020 - November 2021)

Lower mortality with regdanvimab ($p=0.0022$)


Lee et al., Nephrology Dialysis Transp., May 2024

c19early.org

Retrospective 230 hemodialysis patients with COVID-19, showing lower mortality with regdanvimab. Details of the adjusted results are not provided.

Lee

Regdanvimab Lee et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
Retrospective 778 patients in South Korea (November 2020 - February 2021)

Lower severe cases ($p=0.002$) and lower oxygen therapy ($p=0.05$)

Lee et al., Frontiers in Immunology, Nov 2021


c19early.org

Retrospective 778 mild COVID-19 patients showing significantly lower progression to severe disease with regdanvimab treatment.

Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene^{141,142}, vitamin D¹⁴³, etc.) — either because the physician recommending regdanvimab also recommended them, or because the patient seeking out regdanvimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate efficacy.

Park

Regdanvimab Park et al. EARLY TREATMENT



Is early treatment with regdanvimab beneficial for COVID-19?
PSM retrospective 754 patients in South Korea (Dec 2020 - Apr 2021)

Lower progression ($p<0.0001$) and shorter hospitalization ($p<0.0001$)

Park et al., J. Korean Medical Science, Mar 2022


c19early.org

Retrospective propensity score matched analysis of 970 high-risk mild-moderate COVID-19 patients in South Korea, showing regdanvimab significantly reduced risk of disease progression or death by 77% compared to standard care alone. No deaths occurred in either group. Regdanvimab also significantly shortened hospital stay and reduced hematological adverse events.

Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene^{141,142}, vitamin D¹⁴³, etc.) — either because the physician recommending regdanvimab also recommended them, or because the patient seeking out regdanvimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate efficacy.

Streinu-Cercel

Regdanvimab Streinu-Cercel et al. EARLY TREATMENT RCT



Is early treatment with regdanvimab beneficial for COVID-19?

Double-blind RCT 307 patients in multiple countries

Faster recovery with regdanvimab ($p=0.0033$)

Streinu-Cercel et al., Open Forum Infe., Feb 2022

c19early.org

Phase 2 RCT with 307 outpatients with mild-moderate COVID-19, showing regdanvimab (monoclonal antibody) resulted in a minor decrease in time to negative PCR test (primary endpoint) compared to placebo, which was not statistically significant. Regdanvimab did significantly reduce time to clinical recovery by 3 days compared to placebo. A composite outcome of requiring hospitalization or oxygen therapy occurred in 4.4% of regdanvimab patients versus 8.7% placebo, with greater differences in moderate disease patients (7.2% vs 15.8% placebo). No safety issues were identified.

Appendix 1. Methods and Data

Search methods

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org, which regularly receives notification of studies upon publication. Search terms are regdanvimab and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of regdanvimab for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded.

Effect extraction

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome-specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with hospitalization/death than later viral load reduction¹⁴⁴. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO₂ is more important than cough.

Statistical methods

Forest plots are computed using PythonMeta¹⁴⁵ with the DerSimonian and Laird random-effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I^2 statistic. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to Zhang et al. Reported confidence intervals and p -values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported p -values and confidence intervals followed




Fig. 30. Mid-recovery results can more accurately reflect efficacy when almost all patients recover. Mateja et al. confirm that intermediate viral load results more accurately reflect hospitalization/death.

Altman, Altman (B), and Fisher's exact test was used to calculate p -values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1¹⁴⁹. Results are expressed with $RR < 1.0$ favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.14.7) with scipy (1.18.1), pythonmeta (1.26), numpy (2.5.2), statsmodels (0.15.0), and plotly (6.9.0). Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a p -value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

When evaluating potential effect modification across groups, we use an interaction test as described by Altman (C) et al. We compared the log-transformed relative risks using a z -test, deriving the standard error of the difference from the 95% confidence intervals. A two-sided interaction p -value of < 0.05 was considered a statistically significant difference in treatment effect between the groups.

Quality evaluation

Cochrane RoB 2/ROBINS-I are often used to evaluate studies, and have the advantage of providing standardized rules that can be applied with minimal understanding of the domain and study. However, the rules do not account for many real-world issues, often overemphasize or underemphasize others, and studies show low inter-rater reliability¹⁵⁷. Certain domains are more applicable for these tools, however the time-sensitive nature of a pandemic, with significant mortality for every day of delay in evidence assessment, and the characteristics of COVID-19 make them inappropriate for this domain. This can be demonstrated with examples where expert RoB 2/ROBINS-I ratings do not match reality for COVID-19. Popp et al. use RoB 2 to classify Reis et al. as low risk of bias, however this is the opposite of reality—the trial not only has very high risk of bias, but has very high actual known bias, refusing to release data despite pledging to, reporting multiple impossible numbers, having blinding and randomization failure, and many other issues¹⁵⁹. Axfors et al. use RoB 2 to classify Horby et al. as low risk of bias, however this is the opposite of reality—the very late treatment and excessive dosage used produces results with no relevance to recommended usage. HCQ shows poor results with late treatment and excessive dosage, and the combination shows harm^B. Hempenius et al. use ROBINS-I to classify 33 studies for HCQ. The two rated as having the lowest risk of bias^{155,156} are far from the most informative. Both involve very late treatment, providing no information on recommended usage, and ROBINS-I does a very poor job of accounting for the impact of confounding factors^C.

Our quality evaluation focuses on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias. The estimated potential impact of each confounding factor, and the direction of the impact is considered. For example, consider a study that shows significantly lower risk, the value of the study varies significantly if confounding points to an underestimate or an overestimate of efficacy. In one case, the real effect may be null, while the other case provides stronger evidence of efficacy (which may be greater than the study shows). Analysis focusing on the risk of bias, while simpler, may penalize studies for theoretical or technical issues that have no or minimal impact on outcomes. Analysis also depends on the outcome, for example certain issues are less relevant for objective outcomes such as mortality. Inaccurate penalization, and inaccurate high-quality evaluation in the face of known major issues affecting outcomes, increases in significance during a pandemic when immediate recognition of new evidence is critical, and when considering all global studies, as required during a pandemic. Investigators in other countries may have different customs for design, analysis, and reporting, and different English language skills, however they may not be less diligent or have greater bias. Investigators in lower-pharmaceutical-profit countries may have lower bias towards profitable interventions.

Treatment time

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective^{69,70}.

Living analysis

This is a living analysis and is updated regularly. We received no funding, this research is done in our spare time. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/rmeta.html>.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Chae</i> , 3/18/2022, retrospective, South Korea, peer-reviewed, mean age 57.6, 14 authors, study period 1 March, 2021 - 11 May, 2021, average treatment delay 3.68 days.	risk of death, 71.5% lower, RR 0.29, $p = 1.00$, treatment 0 of 25 (0.0%), control 2 of 99 (2.0%), NNT 49, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of mechanical ventilation, 64.0% lower, RR 0.36, $p = 0.46$, treatment 1 of 25 (4.0%), control 11 of 99 (11.1%), NNT 14.
	hospitalization time, 8.6% lower, relative time 0.91, $p = 0.56$, treatment mean 14.32 (± 6.78) $n=25$, control mean 15.67 (± 11.12) $n=99$.
<i>Fomina</i> , 10/20/2023, prospective, Russia, peer-reviewed, 16 authors, study period 20 August, 2022 - 1 February, 2023, this trial compares with another treatment - results may be better when compared to placebo, trial NCT05982704 (history).	risk of no viral clearance, 415.3% higher, RR 5.15, $p = 0.008$, treatment 7 of 24 (29.2%), control 3 of 53 (5.7%).
<i>Hwang</i> , 4/12/2024, retrospective, South Korea, peer-reviewed, 13 authors, study period 26 May, 2021 - 30 January, 2022.	risk of death, 83.3% lower, RR 0.17, $p = 0.12$, treatment 1 of 189 (0.5%), control 6 of 189 (3.2%), NNT 38.
	risk of death, 92.3% lower, RR 0.08, $p = 0.03$, treatment 0 of 189 (0.0%), control 6 of 189 (3.2%), NNT 32, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 30.
	risk of mechanical ventilation, no change, RR 1.00, $p = 1.00$, treatment 1 of 189 (0.5%), control 1 of 189 (0.5%).

<i>Jang</i> , 1/6/2023, retrospective, South Korea, peer-reviewed, 3 authors, study period September 2020 - October 2021.	risk of ICU admission, 33.3% lower, RR 0.67, $p = 0.49$, treatment 8 of 189 (4.2%), control 12 of 189 (6.3%), NNT 47.
	risk of oxygen therapy, 54.8% lower, RR 0.45, $p = 0.01$, treatment 14 of 189 (7.4%), control 31 of 189 (16.4%), NNT 11.
	risk of death, 70.4% lower, RR 0.30, $p = 0.42$, treatment 0 of 418 (0.0%), control 1 of 304 (0.3%), NNT 304, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	hospitalization time, 12.1% lower, relative time 0.88, $p < 0.001$, treatment mean 10.27 (± 2.94) $n=418$, control mean 11.69 (± 4.71) $n=304$.
<i>Jang (B)</i> , 5/16/2022, retrospective, South Korea, peer-reviewed, 3 authors, study period September 2020 - July 2021.	risk of oxygen therapy, 48.5% lower, RR 0.51, $p < 0.001$, treatment 92 of 418 (22.0%), control 130 of 304 (42.8%), NNT 4.8.
	risk of no hospital discharge, 67.8% lower, RR 0.32, $p < 0.001$, treatment 31 of 418 (7.4%), control 70 of 304 (23.0%), NNT 6.4.
	risk of oxygen therapy, 59.6% lower, RR 0.40, $p < 0.001$, treatment 17 of 73 (23.3%), control 79 of 137 (57.7%), NNT 2.9.
	risk of no hospital discharge, 44.1% lower, RR 0.56, $p = 0.03$, treatment 14 of 73 (19.2%), control 47 of 137 (34.3%), NNT 6.6, day 14.
<i>Kim</i> , 5/15/2023, retrospective, South Korea, peer-reviewed, 20 authors, study period December 2020 - September 2021, average treatment delay 3.6 days.	risk of no hospital discharge, 34.9% lower, RR 0.65, $p < 0.001$, treatment 34 of 73 (46.6%), control 98 of 137 (71.5%), NNT 4.0, day 11.
	hospitalization time, 12.9% lower, relative time 0.87, $p = 0.003$, treatment mean 12.1 (± 4.0) $n=73$, control mean 13.9 (± 4.3) $n=137$.
	risk of progression, 51.1% lower, HR 0.49, $p < 0.001$, treatment 1,095, control 1,119, adjusted per study, all, multivariable.
	risk of progression, 33.5% lower, HR 0.67, $p = 0.22$, treatment 1,095, control 1,119, adjusted per study, delta, multivariable.
<i>Kim (B)</i> , 8/8/2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, median age 48.0, 24 authors, study period 18 January, 2021 - 24 April, 2021, average treatment delay 4.0 days, trial NCT04602000 (history).	risk of oxygen therapy, 32.3% lower, HR 0.68, $p < 0.001$, treatment 1,095, control 1,119, adjusted per study, all, multivariable.
	risk of oxygen therapy, 3.7% lower, HR 0.96, $p = 0.83$, treatment 1,095, control 1,119, adjusted per study, delta, multivariable.
	risk of death, 49.8% lower, RR 0.50, $p = 1.00$, treatment 1 of 656 (0.2%), control 2 of 659 (0.3%), NNT 662.
	risk of mechanical ventilation, 85.7% lower, RR 0.14, $p = 0.25$, treatment 0 of 656 (0.0%), control 3 of 659 (0.5%), NNT 220, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of ICU admission, 90.9% lower, RR 0.09, $p = 0.06$, treatment 0 of 656 (0.0%), control 5 of

	659 (0.8%), NNT 132, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). risk of oxygen therapy, 69.2% lower, RR 0.31, $p < 0.001$, treatment 15 of 656 (2.3%), control 49 of 659 (7.4%), NNT 19. risk of hospitalization, 69.1% lower, RR 0.31, $p < 0.001$, treatment 16 of 656 (2.4%), control 52 of 659 (7.9%), NNT 18. risk of progression, 69.7% lower, RR 0.30, $p < 0.001$, treatment 16 of 656 (2.4%), control 53 of 659 (8.0%), NNT 18. risk of progression, 71.6% lower, RR 0.28, $p < 0.001$, treatment 14 of 446 (3.1%), control 48 of 434 (11.1%), NNT 13, high-risk patients. risk of no viral clearance, 32.4% lower, RR 0.68, $p < 0.001$, treatment 612, control 618, inverted to make $RR < 1$ favor treatment.
Lee (B), 5/23/2024, retrospective, South Korea, peer-reviewed, 6 authors, study period 1 December, 2020 - 30 November, 2021, excluded in exclusion analyses: minimal details provided.	risk of death, 59.4% lower, RR 0.41, $p = 0.002$, treatment 10 of 77 (13.0%), control 49 of 153 (32.0%), NNT 5.3, unadjusted.
Lee (C), 11/23/2021, retrospective, South Korea, peer-reviewed, 10 authors, study period 26 November, 2020 - 28 February, 2021.	risk of death, 58.9% lower, RR 0.41, $p = 1.00$, treatment 0 of 234 (0.0%), control 1 of 544 (0.2%), NNT 544, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). risk of severe case, 82.4% lower, HR 0.18, $p = 0.002$, treatment 234, control 234, adjusted per study, propensity score matching, multivariable. risk of oxygen therapy, 45.2% lower, HR 0.55, $p = 0.05$, treatment 234, control 234, adjusted per study, propensity score matching, multivariable. time to discharge, 8.3% lower, relative time 0.92, $p = 0.001$, treatment 234, control 544. risk of no hospital discharge, 76.8% lower, RR 0.23, $p < 0.001$, treatment 5 of 234 (2.1%), control 50 of 544 (9.2%), NNT 14.
Park, 3/29/2022, retrospective, South Korea, peer-reviewed, 5 authors, study period 1 December, 2020 - 16 April, 2021.	risk of progression, 79.4% lower, RR 0.21, $p < 0.001$, treatment 19 of 377 (5.0%), control 81 of 377 (21.5%), NNT 6.1, adjusted per study, odds ratio converted to relative risk, disease aggravation or death, propensity score matching, multivariable. hospitalization time, 13.1% lower, relative time 0.87, $p < 0.001$, treatment mean 11.9 (± 3.3) $n=377$, control mean 13.7 (± 5.4) $n=377$, propensity score matching.
Streinu-Cercel, 2/2/2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries,	risk of mechanical ventilation, 151.2% higher, RR 2.51, $p = 1.00$, treatment 1 of 203 (0.5%), control 0 of 104 (0.0%), continuity correction

peer-reviewed, 17 authors, average treatment delay 3.0 days, trial NCT04602000 (history).

due to zero event (with reciprocal of the contrasting arm).

risk of oxygen therapy, 54.5% lower, RR 0.46, $p = 0.11$, treatment 8 of 203 (3.9%), control 9 of 104 (8.7%), NNT 21.

risk of hospitalization, 48.8% lower, RR 0.51, $p = 0.20$, treatment 9 of 203 (4.4%), control 9 of 104 (8.7%), NNT 24.

composite outcome, 48.8% lower, RR 0.51, $p = 0.20$, treatment 9 of 203 (4.4%), control 9 of 104 (8.7%), NNT 24.

recovery time, 35.2% lower, relative time 0.65, $p = 0.003$, treatment 5.7 [5.2-6.8] $n=203$, control 8.8 [6.8-11.6] $n=104$.

time to viral-, 1.6% lower, relative time 0.98, $p = 0.88$, treatment 12.7 [9.0-12.8] $n=203$, control 12.9 [12.7-13.9] $n=104$.

Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Choi, 3/8/2022, retrospective, South Korea, peer-reviewed, 3 authors.

risk of death, 85.7% lower, RR 0.14, $p = 1.00$, treatment 0 of 65 (0.0%), control 5 of 333 (1.5%), NNT 67, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

risk of oxygen therapy, 76.2% lower, RR 0.24, $p = 0.004$, treatment 4 of 65 (6.2%), control 67 of 333 (20.1%), NNT 7.2, odds ratio converted to relative risk.

Supplementary Data

Supplementary Data

Footnotes

- Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.
- When administered late in infection, HCQ may enhance viral egress by further increasing lysosomal pH beyond the effect of ORF3a's water channel activity, thereby promoting lysosomal exocytosis, inactivating degradative enzymes, and facilitating the release of SARS-CoV-2 particles into the extracellular environment^{151,152}. Research also suggests potential cardioprotective effects at lower doses, but cardiotoxicity with excessive dosage¹⁵³. Bobrowski *et al.* also indicate negative effects if HCQ and remdesivir are combined.
- Peters (B) *et al.* is subject to confounding by calendar-time (SOC evolved rapidly early in the pandemic, the linear covariate does not reflect non-linear SOC changes and hospital specific effects), hospital type (non-treatment hospitals were tertiary university centers), confounding by indication (4/7 hospitals initiated treatment on deterioration), immortal-time bias for as-treated (exposure assigned after baseline), significant differences for other experimental treatments, potential overad-

justment from collider bias (steroid use and indication bias), limited baseline severity information, differences in hospice referral propensity across hospitals, unadjusted difference in time from onset to admission, difference in PCR positivity, and other factors. *Mahévas et al.* is subject to confounding by hospital (treatment highly dependent on the hospital, different SOC/ICU transfer practices, not included in PS), immortal time (only partly addressed in sensitivity analysis), co-treatment differences, calendar-time (SOC evolved rapidly early in the pandemic), binary coding for age (age ≥ 65 despite steep age-risk gradient), residual imbalance (variables dropped from PS), a composite outcome dependent on hospital triage/capacity, and other factors.

References

1. **Haars et al.**, Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, *Microorganisms*, doi:10.3390/microorganisms11102417.
2. **Pochtovyi et al.**, In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, *Vaccines*, doi:10.3390/vaccines11101533.
3. **Focosi et al.**, Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment, *Drug Resistance Updates*, doi:10.1016/j.drug.2023.100991.
4. **Leducq et al.**, Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiad523.
5. **Bruhn et al.**, Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies, *eBioMedicine*, doi:10.1016/j.ebiom.2025.105770.
6. **Ngiam et al.**, Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19, *International Journal of Infectious Diseases*, doi:10.1016/j.ijid.2026.108435.
7. **Choudhary et al.**, Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy, *medRxiv*, doi:10.1101/2021.09.03.21263105.
8. **Günther et al.**, Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection, *medRxiv*, doi:10.1101/2024.01.06.24300890.
9. **Casadevall et al.**, Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship, *Clinical Infectious Diseases*, doi:10.1093/cid/ciae408.
10. **Focosi (B) et al.**, The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?, *Infection and Drug Resistance*, doi:10.2147/IDR.S540928.
11. **Martin-Blondel et al.**, Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study, *iScience*, doi:10.1016/j.isci.2025.114226.
12. **Ryu et al.**, Fibrin drives thromboinflammation and neuropathology in COVID-19, *Nature*, doi:10.1038/s41586-024-07873-4.
13. **Rong et al.**, Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19, *Cell Host & Microbe*, doi:10.1016/j.chom.2024.11.007.
14. **Yang et al.**, SARS-CoV-2 infection causes dopaminergic neuron senescence, *Cell Stem Cell*, doi:10.1016/j.stem.2023.12.012.
15. **Scardua-Silva et al.**, Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
16. **Hampshire et al.**, Cognition and Memory after Covid-19 in a Large Community Sample, *New England Journal of Medicine*, doi:10.1056/NEJMoa2311330.
17. **Duloquin et al.**, Is COVID-19 Infection a Multiorgan Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2, *Journal of Clinical Medicine*, doi:10.3390/jcm13051397.
18. **Sodagar et al.**, Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches, *Biomolecules*, doi:10.3390/biom12070971.
19. **Sagar et al.**, COVID-19-associated cerebral microbleeds in the general population, *Brain Communications*, doi:10.1093/braincomms/fcae127.
20. **Verma et al.**, Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations, *bioRxiv*, doi:10.1101/2024.06.02.596989.
21. **Panagea et al.**, Neurocognitive Impairment in Long COVID: A Systematic Review, *Archives of Clinical Neuropsychology*, doi:10.1093/arclin/aca042.
22. **Ariza et al.**, COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations, *Biomedicine*, doi:10.3390/biomedicine12061147.
23. **Vashisht et al.**, Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications, *Viruses*, doi:10.3390/v16081183.
24. **Ahmad et al.**, Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium, *The Neurohospitalist*, doi:10.1177/19418744241292487.
25. **Wang et al.**, SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction, *Translational Neurodegeneration*, doi:10.1186/s40035-024-00458-1.
26. **Freitas et al.**, Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19, *Scientific Reports*, doi:10.1038/s41598-025-08632-9.
27. **Lu et al.**, Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis, *Nature Communications*, doi:10.1038/s41467-025-61961-1.
28. **Jachman-Kapufka et al.**, Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study, *Brain Sciences*, doi:10.3390/brainsci14111161.
29. **Beckman et al.**, SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19, *Cell Reports*, doi:10.1016/j.celrep.2022.111573.
30. **Eberhardt et al.**, SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, *Nature Cardiovascular Research*, doi:10.1038/s44161-023-00336-5.
31. **Van Tin et al.**, Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF- κ B Signaling, *Cells*, doi:10.3390/cells13161331.
32. **Borka Balas et al.**, COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice, *Reviews in Cardiovascular Medicine*, doi:10.31083/j.rcm2405125.
33. **Altaweel et al.**, An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID-19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies, *Archives of Microbiology & Immunology*, doi:10.26502/ami.936500177.
34. **Saha et al.**, COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications, *Science Progress*, doi:10.1177/00368504251322069.
35. **Yin et al.**, COVID-19: a vascular nightmare unfolding, *Frontiers in Immunology*, doi:10.3389/fimmu.2025.1593885.
36. **Bruno et al.**, Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study, *European Heart Journal*, doi:10.1093/eurheartj/ehaf430.
37. **Abiri et al.**, The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors, *BMC Infectious Diseases*, doi:10.1186/s12879-025-11419-y.
38. **Gioia et al.**, SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence, *Nature Cell Biology*, doi:10.1038/s41556-023-01096-x.

39. **Doğan** et al., *Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients*, Current Issues in Molecular Biology, doi:10.3390/cimb45020062.
40. **Rueda-Torres** et al., *Longitudinal Assessment of DNA Damage in PBMCs From Hospitalized COVID-19 Patients via Alkaline Comet Assay*, Environmental and Molecular Mutagenesis, doi:10.1002/em.70055.
41. **Trender** et al., *Changes in memory and cognition during the SARS-CoV-2 human challenge study*, eClinicalMedicine, doi:10.1016/j.eclinm.2024.102842.
42. **Dugied** et al., *Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization*, Communications Biology, doi:10.1038/s42003-025-07933-z.
43. **Malone** et al., *Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
44. **Murigneux** et al., *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.
45. **Lv** et al., *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.
46. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, Virology, doi:10.1128/mbio.00392-24.
47. **Niarakis** et al., *Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches*, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
48. **Katiyar** et al., *SARS-CoV-2 Assembly: Gaining Infectivity and Beyond*, Viruses, doi:10.3390/v16111648.
49. **Wu** et al., *Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition*, RNA Biology, doi:10.1080/15476286.2024.2433830.
50. **c19early.org**, c19early.org/treatments.html.
51. **Hattab** et al., *SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants*, Infection, doi:10.1007/s15010-024-02223-y.
52. **Focosi (C)**, D., *Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities*, Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268.
53. **Davis** et al., *The Promise and Peril of Anti-SARS-CoV-2 Monoclonal Antibodies*, Clinical Infectious Diseases, doi:10.1093/cid/ciac902.
54. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.
55. **Götzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.
56. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.
57. **Bekelman** et al., *Scope and Impact of Financial Conflicts of Interest in Biomedical Research*, JAMA, doi:10.1001/jama.289.4.454.
58. **Lundh** et al., *Industry sponsorship and research outcome*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000033.pub3.
59. **c19early.org (B)**, c19early.org/rgsupp.html#fig_rctobs.
60. **Concato** et al., *Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs*, New England Journal of Medicine, doi:10.1056/NEJM200006223422507.
61. **Anglemeyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000034.pub2.
62. **c19early.org (C)**, c19early.org/rctobs.html.
63. **Lee** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.
64. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.
65. **Nichol** et al., *Challenging issues in randomised controlled trials*, Injury, 2010, doi:10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
66. **Lee (B)** et al., *Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis*, Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfae069.1573.
67. **altmetric.com**, www.altmetric.com/.
68. **help.altmetric.com**, help.altmetric.com/support/solutions/articles/6000235983-attention-sources-tracked-by-altmetric.
69. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
70. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
71. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.
72. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.
73. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.
74. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.
75. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.
76. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.
77. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.
78. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.
79. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, Research Square, doi:10.21203/rs.3.rs-910467/v1.
80. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, medRxiv, doi:10.1101/2022.01.03.21268111.
81. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, bioRxiv, doi:10.1101/2021.12.31.474653.
82. **Williams, T.**, *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.
83. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.
84. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.

85. **Jitobaom (B)** et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
86. **Jeffreys** et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.
87. **Ostrov** et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, Pathogens, doi:10.3390/pathogens10111514.
88. **Alsaidi** et al., Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model, Marine Drugs, doi:10.3390/md19080418.
89. **Andreani** et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
90. **De Forni** et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, PLoS ONE, doi:10.1371/journal.pone.0276751.
91. **Wan** et al., Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, Scientific Reports, doi:10.1038/s41598-024-54722-5.
92. **Said** et al., The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.
93. **Fiaschi** et al., In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants, Viruses, doi:10.3390/v16020168.
94. **Xing** et al., Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.
95. **Chen** et al., Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir, ACS Pharmacology & Translational Science, doi:10.1021/acspsci.1c00022.
96. **Hempel** et al., Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties, Chemical Science, doi:10.1039/D1SC01494C.
97. **Schultz** et al., Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2, Nature, doi:10.1038/s41586-022-04482-x.
98. **Ohashi** et al., Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment, iScience, doi:10.1016/j.isci.2021.102367.
99. **Al Krad** et al., The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication, bioRxiv, doi:10.1101/2025.03.09.642200.
100. **Abd Elsalam** et al., Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures, AMB Express, doi:10.1186/s13568-026-02030-8.
101. **Rana** et al., Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study, In Silico Pharmacology, doi:10.1007/s40203-026-00576-w.
102. **Setz** et al., Synergistic Virus Neutralizing Activities of European Black Elderberry Fruit Extract and Iota-Carrageenan Against SARS-CoV-2, Influenza A Virus and Respiratory Syncytial Virus, Nutrients, doi:10.3390/nu18081205.
103. **Ali** et al., Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection, Journal of Medical Virology, doi:10.1002/jmv.70713.
104. **Lew** et al., Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections, Cells, doi:10.3390/cells15131146.
105. **Khatun** et al., An All-Oral Antiviral Combination Strategy against COVID-19 Enabled by the Synergistic Mechanism of Action of Auranofin and Remdesivir, Elsevier BV, doi:10.2139/ssrn.6942990.
106. **How** et al., The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages, International Journal of Molecular Sciences, doi:10.3390/ijms27167316.
107. **Tan** et al., Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2021.700502.
108. **Thairu** et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.
109. **Singh** et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac045.
110. **Rothstein**, H., Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments, www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780...
111. **Stanley** et al., Meta-regression approximations to reduce publication selection bias, Research Synthesis Methods, doi:10.1002/jrsm.1095.
112. **Rücker** et al., Arcsine test for publication bias in meta-analyses with binary outcomes, Statistics in Medicine, doi:10.1002/sim.2971.
113. **Peters**, J., Comparison of Two Methods to Detect Publication Bias in Meta-analysis, JAMA, doi:10.1001/jama.295.6.676.
114. **Moreno** et al., Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.
115. **Macaskill** et al., A comparison of methods to detect publication bias in meta-analysis, Statistics in Medicine, doi:10.1002/sim.698.
116. **Egger** et al., Bias in meta-analysis detected by a simple, graphical test, BMJ, doi:10.1136/bmj.315.7109.629.
117. **Harbord** et al., A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints, Statistics in Medicine, doi:10.1002/sim.2380.
118. **Vukovikj** et al., Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024, Eurosurveillance, doi:10.2807/1560-7917.ES.2025.30.10.2400252.
119. **Hwang** et al., Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study, Infectious Diseases and Therapy, doi:10.1007/s40121-024-00971-w.
120. **Fomina** et al., Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period, Frontiers in Immunology, doi:10.3389/fimmu.2023.1259725.
121. **Kim** et al., Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1192512.
122. **Jang** et al., Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.12.035.
123. **Kim (B)** et al., A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac406.
124. **Jang (B)** et al., Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study, Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100675.

125. **Park et al.**, Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study, *Journal of Korean Medical Science*, doi:10.3346/jkms.2022.37.e102.
126. **Chae et al.**, The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study, *Tropical Medicine and Infectious Disease*, doi:10.3390/tropicalmed7030051.
127. **Streinu-Cercel et al.**, Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019, *Open Forum Infectious Diseases*, doi:10.1093/ofid/ofac053.
128. **Lee (C) et al.**, Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease, *Frontiers in Immunology*, doi:10.3389/fimmu.2021.772320.
129. **Choi et al.**, Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study, *Infection & Chemotherapy*, doi:10.3947/ic.2021.0140.
130. **Syed, Y.**, Regdanvimab: First Approval, *Drugs*, doi:10.1007/s40265-021-01626-7.
131. **Lee (D) et al.**, Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study, *International Immunopharmacology*, doi:10.1016/j.intimp.2022.108570.
132. **Feng et al.**, One Thousand SARS-CoV-2 Antibody Structures Reveal Convergent Binding and Near-Universal Immune Escape, *bioRxiv*, doi:10.1101/2025.08.07.669152.
133. **Zeng et al.**, Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future, *Frontiers in Microbiology*, doi:10.3389/fmicb.2023.1232453.
134. **Bubphamanee et al.**, Development of an Antibody Targeting Variants of the SARS-CoV-2 Spike Protein, *Journal of Health Science and Medical Research*, doi:10.31584/jhsmr.20251152.
135. **Kumar (B) et al.**, Advancements in the development of antivirals against SARS-Coronavirus, *Frontiers in Cellular and Infection Microbiology*, doi:10.3389/fcimb.2025.1520811.
136. **Gudima et al.**, Antiviral Therapy of COVID-19, *International Journal of Molecular Sciences*, doi:10.3390/ijms24108867.
137. **Ceja-Gálvez et al.**, Severe COVID-19: Drugs and Clinical Trials, *Journal of Clinical Medicine*, doi:10.3390/jcm12082893.
138. **Liu et al.**, DRAVP: A Comprehensive Database of Antiviral Peptides and Proteins, *Viruses*, doi:10.3390/v15040820.
139. **Gutlapalli et al.**, Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review, *Cureus*, doi:10.7759/cureus.36809.
140. **c19early.org (D)**, c19early.org/timeline.html.
141. **c19early.org (E)**, c19early.org/p.
142. **c19early.org (F)**, c19early.org/ph.
143. **c19early.org (G)**, c19early.org/d.
144. **Mateja et al.**, The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiaf282.
145. **Deng, H.**, PyMeta, Python module for meta-analysis, www.pymeta.com/.
146. **Zhang et al.**, What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, *JAMA*, 80:19, 1690, doi:10.1001/jama.280.19.1690.
147. **Altman, D.**, How to obtain the P value from a confidence interval, *BMJ*, doi:10.1136/bmj.d2304.
148. **Altman (B) et al.**, How to obtain the confidence interval from a P value, *BMJ*, doi:10.1136/bmj.d2090.
149. **Sweeting et al.**, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, *Statistics in Medicine*, doi:10.1002/sim.1761.
150. **Altman (C) et al.**, Interaction revisited: the difference between two estimates, *BMJ*, doi:10.1136/bmj.326.7382.219.
151. **Michelucci et al.**, SARS-CoV-2 ORF3a accessory protein is a water-permeable channel that induces lysosome swelling, *Communications Biology*, doi:10.1038/s42003-024-07442-5.
152. **Ghosh et al.**, β -Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway, *Cell*, doi:10.1016/j.cell.2020.10.039.
153. **Kamga Kapchoup et al.**, In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, *Frontiers in Pharmacology*, doi:10.3389/fphar.2023.1128382.
154. **Bobrowski et al.**, Synergistic and Antagonistic Drug Combinations against SARS-CoV-2, *Molecular Therapy*, doi:10.1016/j.ymthe.2020.12.016.
155. **Peters (B) et al.**, Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine, *Clinical Microbiology and Infection*, doi:10.1016/j.cmi.2020.10.004.
156. **Mahévas et al.**, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, *BMJ* 2020, doi:10.1136/bmj.m1844.
157. **Minozzi et al.**, The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application, *Journal of Clinical Epidemiology*, doi:10.1016/j.jclinepi.2020.06.015.
158. **Popp et al.**, Ivermectin for preventing and treating COVID-19, *Cochrane Database of Systematic Reviews*, doi:10.1002/14651858.CD015017.pub3.
159. **Reis et al.**, Effect of Early Treatment with Ivermectin among Patients with Covid-19, *New England Journal of Medicine*, doi:10.1056/NEJMoa2115869.
160. **Axfors et al.**, Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, *Nature*, doi:10.1038/s41467-021-22446-z.
161. **Horby et al.**, Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial, *NEJM*, doi:10.1056/NEJMoa2022926.
162. **Hempenius et al.**, Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19, *Pharmacoepidemiology and Drug Safety*, doi:10.1002/pds.5632.